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The immune system of the human newborn is capable of responding to every microorganism or 
one of its components it encounters. In fact that is not true, there is one exception. The immune 
system of newborns is unable to respond to the capsular polysaccharides of bacteria such as 
Streptococcus pneumoniae. Because the immune system does not respond, S. pneumoniae can cause 
diseases such as pneumonia, meningitis, bacteremia, and otitis media, and children up to the age 
of 2, maybe even 5  years (1, 2). From personal experience, I recall an episode of otitis media 
during the summer of 1955 as being extremely painful. I cried as loud and long as I could, but the 
substitute for our own family doctor, who was on vacation, was not impressed by the expression 
of my suffering. Fortunately, our own doctor returned just in time so that penicillin saved me and 
I survived. Otitis media is the most common disease caused by S. pneumoniae, but pneumonia is 
the deadliest. Every year, on a worldwide scale, an estimated one and a half million children below 
the age of 5 years die from the consequences of pneumonia (2). Why does the immune system not 
respond to these bacteria, apparently not even try to? Is there a hole in the immune system that lets 
these bacteria in, and although the holes could be rather small, the consequences could be severe. 
The cell-biological answer to this why question could be rather simple: the B lymphocytes of the 
newborn do not express the type 2 complement receptor on their cell surface (3, 4). This receptor is 
crucial for providing a costimulatory signal to the B lymphocyte, which otherwise cannot respond 
to polysaccharides (5). At the age of approximately 2 years, the B lymphocytes start to express this 
receptor, acquire the capacity to respond, and produce antibodies to the polysaccharide, and from 
that point on the child is protected (6, 7). But keep in mind that nobody is really sure whether all 
pneumococcal serotypes would activate B lymphocytes in a similar way. This, however, still does 
not quite answer the why question. Why does it take so long to develop responsiveness, and, what 
is the evolutionary benefit? It could be hypothesized that S. pneumoniae can colonize the mucosal 
surfaces of the upper respiratory tract of young children because the immune system does not react 
(8). By doing so, it occupies all available niches, leaving no place for other bacterial pathogens. 
This will protect young children against many other infectious diseases, but the pay-off for this 
protection is the burden of pneumonia.
When an immune system is not strong enough, it can be enhanced by vaccination. For S. 
pneumoniae that does not work for young children, because a polysaccharide vaccine would not 
induce an immune response. If you cannot change the human host, and if you cannot change the 
bacterium, then the only solution left is to change the vaccine. That is exactly what has been done 
by Oswald Avery, back in 1929 (9). His breakthrough discovery, believed by many to be of Nobel 
prize-winning magnitude, was that by covalent coupling of a protein to the bacterial polysac-
charide you can change the nature of the immune response to the polysaccharide. Conjugation 
of protein to polysaccharide is the reason, the magic trick if you want, which makes that infants 
can respond to the vaccine, and be protected against pneumococcal infections. This discovery 
by Avery was made at the right place (the Rockefeller Institute in New York) but certainly at the 
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wrong time (namely, in 1929). During that period, it was not 
fashionable to study prevention of infectious diseases because 
it was believed that antibiotics would make such studies obso-
lete. The enormous success of antibiotics prompted the US 
Surgeon General, William Stewart, in 1969 to address the US 
Congress. He said it was time to “close the books on infectious 
diseases.” This famous quote has been repeated innumerable 
times to underscore how wrong he was. The original source of 
this quote however is difficult, if not impossible to trace, and 
therefore, it may very well be an urban legend (10). Closer to 
immunology, Sir McFarlane Burnet wrote in 1962: “One can 
think of the middle of the twentieth century as the end of one 
of the most important social revolutions in history, the virtual 
elimination of the infectious diseases as a significant factor in 
social life” (11). If being wrong could be graded, Burnet would 
deserve an A+.
Because of the above illustrations of the widespread belief 
of the supremacy of man over microbe, it took almost 50 years 
before the principles of Oswald Avery were rediscovered and 
polysaccharide conjugate vaccines were developed and became 
available (12). The story of pneumococcal vaccines is complicated 
because for the immune system, S. pneumoniae is not one single 
bacterium but at least 93 recognized different ones (13), such 
as cellophane flowers of yellow and green. That is because the 
capsular polysaccharide comes in different compositions, and an 
ideal vaccine thus should be composed of all these 93 polysaccha-
rides. Fortunately, the top 13 polysaccharides cover most (close 
to 80%) of all pneumococcal infections. This top 13 is the top 13 
of pneumococcal infections in White, American children (10). 
Approximately 20 years ago today, the pneumococcal conjugate 
vaccine also was introduced in Europe and the Netherlands. The 
coverage of the 13-valent vaccine in other parts of the world, 
such as South-East Asia and Africa, unfortunately is substantially 
lower (14). We are studying which pneumococcal serotypes cause 
disease in children from Bangladesh, a sub-study of a large global 
initiative (15). The ultimate goal is to identify the pneumococci 
and other microorganisms that cause childhood pneumonia and 
subsequently design and implement effective vaccines that can 
improve survival rates of children across the globe.
Not only during childhood but also later in life, usually much 
later in life, you will meet S. pneumoniae again. “You’ll be older 
too, and if you say the word, I could stay with you” could be the 
motto of the pneumococci. William Osler touched upon this sub-
ject in The Principles and Practice of Medicine, a textbook which 
was first published in 1892 and remained in print for 55 years and 
16 editions.1 In the first edition, in the chapter on Diseases of the 
Respiratory System, Osler describes on page 526 the prognosis 
of pneumonia: “In children and in healthy adults the outlook is 
good. In the debilitated, in drunkards, and in the aged the chances 
are against recovery. So fatal is it in the latter class that it has 
been termed the natural end of the old man.” In the third edition 
of his book, this last sentence has been rephrased. It now reads 
as “Pneumonia may well be called the friend of the aged. Taken 
off by it in an acute, short, not often painful illness, the old man 
1 http://archive.org/details/principlesandpr00mccrgoog 
escapes those ‘cold gradations of decay’ so distressing to himself 
and to his friends.” Since that time, pneumonia has been termed 
the old man’s friend, although it sacrificed most of our lives. It 
is ironical that in 1919, Osler himself died after a protracted 
pneumonia. But that was more than 20 years ago, in fact almost 
100  years ago, 10  years before Fleming discovered penicillin. 
The 13-valent pneumococcal conjugate vaccine has shown to be 
effective in elderly (16, 17) and hopefully will be implemented in 
the near future.
Clearly, because of the fact that 93 serotypes of S. pneumoniae 
exist, a vaccine with 100% coverage will be virtually impossible 
to achieve. Thus, although prevention would be preferred, there 
will always be the need for treatment of pneumococcal infections. 
Patients with pneumococcal pneumonia now can be treated with 
antibiotics, penicillin, or other antibiotics, and most of them 
survive. The mortality rate of pneumococcal pneumonia has 
dropped from 50% to below 5% (18). After all, there may have 
been some truth in the statement of Surgeon General William 
Stewart. Most of the clinical symptoms of the pneumonia now in 
fact are caused by an overactive immune system. That is because 
the immune system has no way of knowing that antibiotics have 
already killed the bacteria, shortly after the start of the infection. 
The fragments of killed bacteria are an even stronger stimulus 
for the immune system (19). Is this really to the benefit of 
Mr. Kite, to the Hendersons, or any other patient with pneumo-
coccal pneumonia? Can one desire too much of a good thing, 
is what Rosalind asks Orlando in Shakespeare’s As You Like It 
(1600).2 Apparently yes, you can have too much of a good immune 
response. Therefore, it is attractive to postulate that dampening 
the immune response, thereby reducing inflammation, during 
pneumococcal pneumonia could have a clinical beneficial effect. 
Treatment with anti-inflammatory drug, such as dexamethasone 
indeed, reduces the length of hospital stay and improves quality of 
life afterward (20, 21). The combined effect of optimal vaccination 
strategies and balanced antibiotic and anti-inflammatory treat-
ment thus has dramatically improved the outlook for prevention 
and recovery of pneumococcal infection, both for the very young 
and the very old. It is getting better all the time.
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